News
OBI Pharma Announces Discontinuation of the Phase 1/2 Study of its Antibody- OBI 888 to focus on other priority Cancer programs
OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced …
Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, and OBI-3424
Title: A phase 3, randomized, open-label study of the anti-Globo …
OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth
Poster Presentations to highlight the ongoing clinical studies targeting Globo …
Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science
Title: OBI-3424, an AKR1C3-activated prodrug, exhibits in vivo synergistic anti-tumor …
OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science
Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 …
OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau
OBI is eligible to receive up to US$ 200 million …
OBI Pharma Announces Its In-house COVID-19 Vaccine, BCVax, can induce potent antibodies to neutralize against all variants
OBI Pharma Inc. (TPEx: 4174) announced today research results in …
OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424
SOLID TUMOR PATIENTS WITH HIGH GLOBO H OR AKR1C3 EXPRESSION …
OBI Pharma Announces First Cancer Patient Enrolled on OBI-999 in Phase 2 Study
OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced …
OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL
First clinical trial to evaluate the safety and efficacy of …